INV03
Modulation of host immunity in the airways with interferon lambda encoding mRNA
C Plank(1,2) A Macht(1) Y Huang(2) L S Reinert(3) V Grass(2) E T Aristizabal Prada(1) E Babel(1) A Semmler(1) A Wegner(1) E Lichtenegger-Hartl(1) S Haas(1) G Hasenpusch(1) S Meyer(1) S R Paludan(3) A Pichlmair(2) C Rudolph(1,4) T Langenickel(1)
1:Ethris GmbH; 2:Technische Universität München; 3:Aarhus University; 4:Ludwig-Maximilians-Universitat München
Type III interferons play an important role in the innate antiviral, antifungal and antiprotozoal defences of mucosal barriers and enhance adaptive immune responses in the respiratory mucosa. Based on its proprietary Stabilized Non-Immunogenic mRNA (SNIM®RNA) and lipidoid nanoparticle delivery platforms, Ethris has developed interferon lambda encoding mRNA as a drug candidate for prophylactic and therapeutic administration to the airways for prevention and treatment of viral infections. In the presentation, formulation of mRNA suitable for administration to the airways as an aerosol will be discussed. Furthermore, preclinical proof of concept data will be presented, demonstrating the potency of interferon lambda endcoding mRNA in mouse and ferret influenza A and SARS-CoV-2 virus challenge models in mice and ferrets when administered to the airways.